ALNY Stock Recent News

Alnylam Pharmaceuticals (ALNY 0.21%), known for its innovative RNA interference (RNAi) therapeutics, released its fourth-quarter earnings on Feb. 13. The company's non-GAAP earnings per share (EPS) came in at $0.06, significantly better than analysts' consensus prediction for a loss of $0.60 per share.

Start Time: 08:30 January 1, 0000 9:28 AM ET Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q4 2024 Earnings Conference Call February 13, 2025, 08:30 AM ET Company Participants Yvonne Greenstreet - CEO Tolga Tanguler - Chief Commercial Officer Pushkal Garg - CMO Jeff Poulton - CFO Christine Lindenboom - Chief Corporate Communications Officer Conference Call Participants Tazeen Ahmad - Bank of America Kostas Biliouris - BMO Capital Markets Gena Wang - Barclays Maury Raycroft - Jefferies Ritu Baral - TD Cowen Teraesa Vitelli - Scotiabank Gary Nachman - Raymond James Jessica Fye - JPMorgan Paul Matteis - Stifel Salveen Richter - Goldman Sachs Ellie Merle - UBS Mani Foroohar - Leerink Partners Luca Issi - RBC Capital Markets Operator Good morning, ladies and gentlemen, and welcome to the Alnylam Pharmaceuticals Fourth Quarter Full Year 2024 Earnings Conference Call. At this time, all lines are in a listen-only mode.

Although the revenue and EPS for Alnylam (ALNY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to loss of $1.10 per share a year ago.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?

We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.

Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors can boost returns by adding these top-ranked liquid stocks, Alnylam Pharmaceuticals, Frontdoor, EverQuote and Sezzle, to their portfolios.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2024 on Thursday, February 13, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss fourth quarter and year-end 2024 results as well as expectations for the future via conference call on Thursday, February 13, 2025 at 8.